| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $47.0M | +55.1% |
| SG&A Expense | $21.6M | +187.5% |
| Operating Income | -$68.6M | -81.5% |
| Income Tax | $0 | — |
| Net Income | -$61.4M | -69.2% |
| EPS (Basic) | -$2.50 | +74.3% |
| EPS (Diluted) | -$2.50 | +74.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $168.2M | +103.8% |
| Current Assets | $169.3M | +98.3% |
| Total Assets | $177.5M | +104.9% |
| Current Liabilities | $10.0M | +78.4% |
| Long-term Debt | $10.3M | +4.0% |
| Total Liabilities | $26.1M | +55.0% |
| Stockholders' Equity | $151.5M | +311.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$47.4M | -41.8% |
| Capital Expenditures | $2.1M | +341.5% |
| Investing Cash Flow | -$2.1M | -341.5% |
| Financing Cash Flow | $135.7M | +99.2% |
| Free Cash Flow | -$49.5M | -45.9% |